525 related articles for article (PubMed ID: 25256873)
1. Evaluation of the pro-inflammatory cytokine tumor necrosis factor-α in adolescents with polycystic ovary syndrome.
Pawelczak M; Rosenthal J; Milla S; Liu YH; Shah B
J Pediatr Adolesc Gynecol; 2014 Dec; 27(6):356-9. PubMed ID: 25256873
[TBL] [Abstract][Full Text] [Related]
2. Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents.
Li L; Chen X; He Z; Zhao X; Huang L; Yang D
J Pediatr Adolesc Gynecol; 2012 Dec; 25(6):390-5. PubMed ID: 23089573
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome.
Gonzalez F; Thusu K; Abdel-Rahman E; Prabhala A; Tomani M; Dandona P
Metabolism; 1999 Apr; 48(4):437-41. PubMed ID: 10206434
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index.
Samy N; Hashim M; Sayed M; Said M
Dis Markers; 2009; 26(4):163-70. PubMed ID: 19729797
[TBL] [Abstract][Full Text] [Related]
5. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.
Silfen ME; Denburg MR; Manibo AM; Lobo RA; Jaffe R; Ferin M; Levine LS; Oberfield SE
J Clin Endocrinol Metab; 2003 Oct; 88(10):4682-8. PubMed ID: 14557441
[TBL] [Abstract][Full Text] [Related]
6. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels.
Piouka A; Farmakiotis D; Katsikis I; Macut D; Gerou S; Panidis D
Am J Physiol Endocrinol Metab; 2009 Feb; 296(2):E238-43. PubMed ID: 18957615
[TBL] [Abstract][Full Text] [Related]
7. The impact of body mass on inflammatory markers and insulin resistance in polycystic ovary syndrome.
Souza Dos Santos AC; Soares NP; Costa EC; de Sá JC; Azevedo GD; Lemos TM
Gynecol Endocrinol; 2015 Mar; 31(3):225-8. PubMed ID: 25373529
[TBL] [Abstract][Full Text] [Related]
8. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea.
Vgontzas AN; Trakada G; Bixler EO; Lin HM; Pejovic S; Zoumakis E; Chrousos GP; Legro RS
Metabolism; 2006 Aug; 55(8):1076-82. PubMed ID: 16839844
[TBL] [Abstract][Full Text] [Related]
9. The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome.
Yang HY; Ma Y; Lu XH; Liang XH; Suo YJ; Huang ZX; Lu DC; Qin YF; Luo ZJ
Ann Endocrinol (Paris); 2015 Oct; 76(5):620-7. PubMed ID: 26514948
[TBL] [Abstract][Full Text] [Related]
10. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
11. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism.
Castelo-Branco C; Steinvarcel F; Osorio A; Ros C; Balasch J
Gynecol Endocrinol; 2010 Oct; 26(10):736-42. PubMed ID: 20569105
[TBL] [Abstract][Full Text] [Related]
12. Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis.
Li L; Feng Q; Ye M; He Y; Yao A; Shi K
J Obstet Gynaecol; 2017 Nov; 37(8):1036-1047. PubMed ID: 28657375
[TBL] [Abstract][Full Text] [Related]
13. The effect of weight loss on inflammation in obese women with polycystic ovary syndrome.
Olszanecka-Glinianowicz M; Zahorska-Markiewicz B; Kocełak P; Janowska J; Semik-Grabarczyk E
Endokrynol Pol; 2008; 59(1):13-7. PubMed ID: 18335395
[TBL] [Abstract][Full Text] [Related]
14. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.
Kurek Eken M; Sahin Ersoy G; Yayla Abide C; Sanverdi İ; Devranoglu B; Kutlu T; Çevik Ö
J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233
[TBL] [Abstract][Full Text] [Related]
15. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.
Holte J; Bergh T; Gennarelli G; Wide L
Clin Endocrinol (Oxf); 1994 Oct; 41(4):473-81. PubMed ID: 7955458
[TBL] [Abstract][Full Text] [Related]
16. Ultrasonographic and biochemical assessments as early prediction of polycystic ovarian syndrome in obese women.
Ahmed AA; Moselhy SS; Kumosani TA; Huwait EA; Al-Ghamdi MA; Al-Madani KA; AlToukhi MH; Kumosani AT
Afr Health Sci; 2020 Jun; 20(2):676-681. PubMed ID: 33163031
[TBL] [Abstract][Full Text] [Related]
17. Adipokines, insulin-like growth factor binding protein-3 levels, and insulin sensitivity in women with polycystic ovary syndrome.
Lee H; Oh JY; Sung YA
Korean J Intern Med; 2013 Jul; 28(4):456-63. PubMed ID: 23864804
[TBL] [Abstract][Full Text] [Related]
18. Omentin-1 level in adolescents with polycystic ovarian syndrome.
Özgen İT; Oruçlu Ş; Selek S; Kutlu E; Guzel G; Cesur Y
Pediatr Int; 2019 Feb; 61(2):147-151. PubMed ID: 30566253
[TBL] [Abstract][Full Text] [Related]
19. Comparison of serum anti-Müllerian hormone levels in normal weight and overweight-obese adolescent patients with polycystic ovary syndrome.
Cengiz H; Ekin M; Dagdeviren H; Yildiz Ş; Kaya C; Kanawati A
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():46-50. PubMed ID: 25036408
[TBL] [Abstract][Full Text] [Related]
20. An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients.
Liao Y; Huang R; Sun Y; Yue J; Zheng J; Wang L; Tao T; Ma J; Li S; Liu W
Reprod Biol Endocrinol; 2017 Jan; 15(1):9. PubMed ID: 28125989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
